Comparative Pharmacology
Head-to-head clinical analysis: ORPHENADRINE CITRATE ASPIRIN AND CAFFEINE versus SOMA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENADRINE CITRATE ASPIRIN AND CAFFEINE versus SOMA.
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE vs SOMA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orphenadrine citrate is a centrally acting muscle relaxant with anticholinergic properties; aspirin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis; caffeine is a central nervous system stimulant that antagonizes adenosine receptors.
Centrally acting muscle relaxant; acts at brainstem reticular formation and spinal cord levels to inhibit polysynaptic reflexes, possibly via GABAergic and monoaminergic pathways.
1-2 tablets (orphenadrine citrate 50 mg, aspirin 770 mg, caffeine 60 mg per tablet) orally every 8-12 hours as needed; maximum 4 tablets per day.
250 mg to 350 mg orally three times daily and at bedtime.
None Documented
None Documented
Orphenadrine: ~14 hours (range 12-16 h); Aspirin: 2-3 h for low doses, 15-30 h for high/anti-inflammatory doses due to saturable metabolism; Caffeine: 3-6 h in adults, prolonged in liver disease.
1-2 hours; prolonged to 3-4 hours in hepatic impairment; parent drug rapidly cleared via CYP2C19 metabolism to meprobamate (active, t1/2 6-16 hours).
Orphenadrine: ~60% renal (metabolites, <8% unchanged), ~20% biliary/fecal; Aspirin: ~80-100% renal (salicylates, dose-dependent; alkaline urine increases excretion); Caffeine: ~1-3% renal (unchanged), main metabolites renal.
Renal: ~60-70% as metabolites (including meprobamate and glucuronide conjugates); fecal: minimal; biliary: negligible.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant